Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports

被引：0
|
作者：
Chang, L.
Dhruva, S. S.
Chu, J.
Bero, L. A.
Redberg, R. F.
机构：
来源：
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2016年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：22 / 23
页数：2
相关论文
共 18 条
  • [1] Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports
    Chang, Lee
    Dhruva, Sanket S.
    Chu, Janet
    Bero, Lisa A.
    Redberg, Rita F.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [2] Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study
    Phillips, Adam T.
    Rathi, Vinay K.
    Ross, Joseph S.
    [J]. JAMA INTERNAL MEDICINE, 2016, 176 (04) : 551 - 552
  • [3] Comparison of Priority vs Standard US Food and Drug Administration Premarket Approval Review for High-Risk Medical Devices
    Ong, Caroline
    Ly, Vy K.
    Redberg, Rita F.
    [J]. JAMA INTERNAL MEDICINE, 2020, 180 (05) : 801 - 803
  • [4] Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA
    Matthew J. Swanson
    James L. Johnston
    Joseph S. Ross
    [J]. Trials, 22
  • [5] Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA
    Swanson, Matthew J.
    Johnston, James L.
    Ross, Joseph S.
    [J]. TRIALS, 2021, 22 (01)
  • [6] Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
    Olivier, Timothee
    Haslam, Alyson
    Prasad, Vinay
    [J]. BMC CANCER, 2023, 23 (01)
  • [7] Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
    Timothée Olivier
    Alyson Haslam
    Vinay Prasad
    [J]. BMC Cancer, 23
  • [8] Market competition among manufacturers of novel high-risk therapeutic devices receiving FDA premarket approval between 2001 and 2018
    Rathi, Vinay K.
    Johnston, James L.
    Dhruva, Sanket
    Ross, Joseph
    [J]. BMJ SURGERY INTERVENTIONS & HEALTH TECHNOLOGIES, 2023, 5 (01)
  • [9] Characteristics and use of patient-reported outcomes of clinical trials for high-risk neurological medical devices that received FDA premarket approval from 2001 to 2022
    Ryan, Morgan E.
    Srivastava, Siddharth
    Wan, Lin
    Yang, Guang
    Zhang, Bo
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 37
  • [10] Pivotal clinical trials with patient-reported outcome measures in premarket approval applications for high-risk medical devices from 2005 to 2018: Review, examples, and regulatory considerations
    Zhang, Bo
    Shankara, Sravya B.
    Guo, Jing
    Zhang, Hui
    [J]. CONTEMPORARY CLINICAL TRIALS, 2022, 116
12